Literature DB >> 15305162

Mortality from cutaneous malignant melanoma in Europe. Has the epidemic levelled off?

Cristina Bosetti1, Carlo La Vecchia, Luigi Naldi, Franca Lucchini, Eva Negri, Fabio Levi.   

Abstract

Trends of mortality from cutaneous malignant melanoma (CMM) between 1960 and 1999 in several European countries and the European Union (EU) as a whole have been reviewed, using death certification data for skin cancer available from the World Health Organization. Separate analyses were performed for young (i.e., age 20-44 years) and middle-aged (i.e., age 45-64 years) adults, among whom around 80-90% of skin cancer deaths are attributable to CMM. After steady rises between 1960 and 1990, skin cancer rates among young adults have tended to decline since the mid-1990s in several European countries, with a fall of 14% in men and of 11% in women in the EU as a whole. In middle-aged adults, the trends were less favourable, although mortality started to level off since the mid-1990s. Thus, our data provide further evidence of an improvement of CMM mortality trends in recent years in several European countries. The particularly favourable trends in young people suggest that a further decline in mortality from CMM in Europe is likely to occur within the next few years. Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2004        PMID: 15305162     DOI: 10.1097/01.cmr.0000136710.75287.1c

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

1.  A multilingual assessment of melanoma information quality on the Internet.

Authors:  Lilla Bari; Lajos Kemeny; Ferenc Bari
Journal:  J Cancer Educ       Date:  2014-06       Impact factor: 2.037

Review 2.  Epidemiology and prevention of cutaneous melanoma.

Authors:  Marie-France Demierre
Journal:  Curr Treat Options Oncol       Date:  2006-05

3.  Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study).

Authors:  Christine Fink; Maja Hofmann; Agata Jagoda; Iris Spaenkuch; Andrea Forschner; Ioanna Tampouri; Diana Lomberg; Dieter Leupold; Claus Garbe; Holger A Haenssle
Journal:  BMJ Open       Date:  2016-12-19       Impact factor: 2.692

4.  Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program.

Authors:  Bernardo L Rapoport; Daniel A Vorobiof; Lydia M Dreosti; Adam Nosworthy; Georgina McAdam; Johan P Jordaan; Helen Miller-Jansön; Margreet de Necker; Janetta C de Beer; Hennie Duvenhage
Journal:  J Glob Oncol       Date:  2016-11-02

5.  Changing Trends in Melanoma Incidence and Decreasing Melanoma Mortality in Hungary Between 2011 and 2019: A Nationwide Epidemiological Study.

Authors:  Gabriella Liszkay; Zoltan Kiss; Roland Gyulai; Judit Oláh; Péter Holló; Gabriella Emri; András Csejtei; István Kenessey; Angela Benedek; Zoltán Polányi; Zsófia Nagy-Erdei; Andrea Daniel; Kata Knollmajer; Máté Várnai; Zoltán Vokó; Balázs Nagy; György Rokszin; Ibolya Fábián; Zsófia Barcza; Csaba Polgár
Journal:  Front Oncol       Date:  2021-02-12       Impact factor: 6.244

6.  A comparison of trends in melanoma mortality in New Zealand and Australia: the two countries with the highest melanoma incidence and mortality in the world.

Authors:  Mary Jane Sneyd; Brian Cox
Journal:  BMC Cancer       Date:  2013-08-06       Impact factor: 4.430

7.  Melanoma incidence and mortality in Scotland 1979-2003.

Authors:  R M MacKie; C Bray; J Vestey; V Doherty; A Evans; D Thomson; M Nicolson
Journal:  Br J Cancer       Date:  2007-05-29       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.